Modus Therapeutics AB
556669-2199ActiveSwedish biotech developing sevuparin for severe inflammatory diseases.
Biotechnology Companymodustx.com
Yleiskatsaus
- Tuntematon
- Työntekijät
- Tuntematon
- Liikevaihto
- 2004
- Perustettu
Avainpäättäjät
John Öhd
Chief Executive Officer
@modustx.com+46707XXXXXX
Johan Dighed
Board member
@modustx.com
Viktor Drvota
Chairman
@modustx.com
Michael Forer
Member of the Nomination Committee
@modustx.com
+3 lisää yhteystietoja Funnelfeedrissä
Kuvaus
Modus Therapeutics is a Swedish biotechnology company focused on developing novel treatments for severe medical conditions with high unmet needs. Their proprietary polysaccharide, sevuparin, is the core asset under development. Sevuparin is designed as a heparinoid that modifies inflammation while m...